Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 8
2012 7
2013 5
2014 7
2015 8
2016 8
2017 4
2018 5
2019 5
2020 5
2021 5
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin.
Kaufmann CC, Ahmed A, Kassem M, Freynhofer MK, Jäger B, Aicher G, Equiluz-Bruck S, Spiel AO, Vafai-Tabrizi F, Gschwantler M, Fasching P, Wojta J, Giannitsis E, Huber K. Kaufmann CC, et al. Clin Res Cardiol. 2022 Mar;111(3):343-354. doi: 10.1007/s00392-021-01970-4. Epub 2021 Nov 15. Clin Res Cardiol. 2022. PMID: 34782921 Free PMC article.
Effect of marathon and ultra-marathon on inflammation and iron homeostasis.
Kaufmann CC, Wegberger C, Tscharre M, Haller PM, Piackova E, Vujasin I, Kassem M, Tentzeris I, Freynhofer MK, Jäger B, Wojta J, Huber K. Kaufmann CC, et al. Scand J Med Sci Sports. 2021 Mar;31(3):542-552. doi: 10.1111/sms.13869. Epub 2020 Nov 17. Scand J Med Sci Sports. 2021. PMID: 33140866
Corrigendum to "Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention" [Atherosclerosis 270 (2018) 173-179].
Tscharre M, Herman R, Rohla M, Hauser C, Farhan S, Freynhofer MK, Huber K, Weiss TW. Tscharre M, et al. Atherosclerosis. 2020 Aug;306:96. doi: 10.1016/j.atherosclerosis.2020.05.001. Epub 2020 Jul 13. Atherosclerosis. 2020. PMID: 32674806 No abstract available.
Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study.
Freynhofer MK, Hein-Rothweiler R, Haller PM, Aradi D, Dézsi DA, Gross L, Orban M, Trenk D, Geisler T, Huczek Z, Toth-Gayor GG, Massberg S, Huber K, Sibbing D. Freynhofer MK, et al. Thromb Haemost. 2019 Apr;119(4):660-667. doi: 10.1055/s-0038-1677549. Epub 2019 Jan 29. Thromb Haemost. 2019. PMID: 30695790 Clinical Trial.
Impact of On-Site Cardiac Surgery on Clinical Outcomes After Transfemoral Transcatheter Aortic Valve Replacement.
Egger F, Zweiker D, Freynhofer MK, Löffler V, Rohla M, Geppert A, Farhan S, Vogel B, Falkensammer J, Kastner J, Pichler P, Vock P, Lamm G, Luha O, Schmidt A, Scherr D, Hammerer M, Hoppe UC, Maurer E, Grund M, Lambert T, Tkalec W, Sturmberger T, Zeindlhofer E, Grabenwöger M, Huber K; Austrian TAVI Group. Egger F, et al. JACC Cardiovasc Interv. 2018 Nov 12;11(21):2160-2167. doi: 10.1016/j.jcin.2018.07.015. JACC Cardiovasc Interv. 2018. PMID: 30409272 Free article.
Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin Therapy.
Tentzeris I, Farhan S, Freynhofer MK, Rohla M, Jarai R, Vogel B, Baumgartner-Parzer S, Nürnberg M, Geppert A, Wessely E, Wojta J, Huber K, Kautzky-Willer A. Tentzeris I, et al. Am J Cardiol. 2017 Sep 1;120(5):747-752. doi: 10.1016/j.amjcard.2017.05.045. Epub 2017 Jun 15. Am J Cardiol. 2017. PMID: 28734463
Platelet turnover predicts outcome after coronary intervention.
Freynhofer MK, Iliev L, Bruno V, Rohla M, Egger F, Weiss TW, Hübl W, Willheim M, Wojta J, Huber K. Freynhofer MK, et al. Thromb Haemost. 2017 May 3;117(5):923-933. doi: 10.1160/TH16-10-0785. Epub 2017 Feb 23. Thromb Haemost. 2017. PMID: 28229159 Free PMC article.
Systematic screening for cardiovascular risk at pharmacies.
Rohla M, Haberfeld H, Sinzinger H, Kritz H, Tscharre M, Freynhofer MK, Huber K, Weiss TW. Rohla M, et al. Open Heart. 2016 Sep 19;3(2):e000497. doi: 10.1136/openhrt-2016-000497. eCollection 2016. Open Heart. 2016. PMID: 27738518 Free PMC article.
Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experience.
Rohla M, Tentzeris I, Freynhofer MK, Farhan S, Jarai R, Egger F, Weiss TW, Wojta J, Geppert A, Kastrati A, Stone GW, Huber K. Rohla M, et al. Wien Klin Wochenschr. 2016 Dec;128(23-24):906-915. doi: 10.1007/s00508-016-1078-6. Epub 2016 Sep 13. Wien Klin Wochenschr. 2016. PMID: 27624328 Free PMC article.
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Aradi D, et al. Eur Heart J. 2015 Jul 14;36(27):1762-71. doi: 10.1093/eurheartj/ehv104. Epub 2015 Apr 20. Eur Heart J. 2015. PMID: 25896078 Review.
High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch block occurring during transcatheter aortic valve implantation.
Egger F, Nürnberg M, Rohla M, Weiss TW, Unger G, Smetana P, Geppert A, Gruber SC, Bambazek A, Falkensammer J, Waldenberger FR, Huber K, Freynhofer MK. Egger F, et al. Heart Rhythm. 2014 Dec;11(12):2176-82. doi: 10.1016/j.hrthm.2014.07.014. Epub 2014 Jul 14. Heart Rhythm. 2014. PMID: 25034184 Free article.
Influence of high-dose highly efficient statins on short-term mortality in patients undergoing percutaneous coronary intervention with stenting for acute coronary syndromes.
Tentzeris I, Rohla M, Jarai R, Farhan S, Freynhofer MK, Unger G, Nürnberg M, Geppert A, Wessely E, Wojta J, Huber K. Tentzeris I, et al. Am J Cardiol. 2014 Apr 1;113(7):1099-104. doi: 10.1016/j.amjcard.2013.12.012. Epub 2014 Jan 14. Am J Cardiol. 2014. PMID: 24462073 Clinical Trial.
Biomarkers in acute coronary artery disease.
Freynhofer MK, Tajsić M, Wojta J, Huber K. Freynhofer MK, et al. Wien Med Wochenschr. 2012 Nov;162(21-22):489-98. doi: 10.1007/s10354-012-0148-2. Epub 2012 Nov 10. Wien Med Wochenschr. 2012. PMID: 23143510 Review.
The role of platelets in athero-thrombotic events.
Freynhofer MK, Bruno V, Wojta J, Huber K. Freynhofer MK, et al. Curr Pharm Des. 2012;18(33):5197-214. doi: 10.2174/138161212803251899. Curr Pharm Des. 2012. PMID: 22724408 Review.
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, Ecollan P, Combes X, Huber K, Pollack C Jr, Bénezet JF, Stibbe O, Filippi E, Teiger E, Cayla G, Elhadad S, Adnet F, Chouihed T, Gallula S, Greffet A, Aout M, Collet JP, Vicaut E; ATOLL Investigators. Montalescot G, et al. Lancet. 2011 Aug 20;378(9792):693-703. doi: 10.1016/S0140-6736(11)60876-3. Lancet. 2011. PMID: 21856483 Clinical Trial.
56 results